TY - JOUR
T1 - Immunopathological mechanisms in multiple sclerosis
AU - Podojil, Joseph R.
AU - Miller, Stephen D.
N1 - Funding Information:
This work was supported in part by U.S. Public Health Service, National Institutes of Health Grants NS-034819 and NS-026543, National Multiple Sclerosis Society Grant RG-3489-A-6-2, and by support from the Myelin Repair Foundation. J.R.P. is supported by training grant, NIH T32 AG000260 ‘Drug Discovery Training in Age-related Disorders’.
PY - 2006
Y1 - 2006
N2 - Genetic indicators that correlate with a predisposition for multiple sclerosis (MS) have been identified. The expression of specific major histocompatibility complex class II (MHC II) haplotypes and altered variants of costimulatory molecules, for example, cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), are hypothesized to allow for aberrant activation of myelin-specific autoreactive T cells. The current review focuses on possible mechanisms by which the expression of these proteins contribute to disease.
AB - Genetic indicators that correlate with a predisposition for multiple sclerosis (MS) have been identified. The expression of specific major histocompatibility complex class II (MHC II) haplotypes and altered variants of costimulatory molecules, for example, cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), are hypothesized to allow for aberrant activation of myelin-specific autoreactive T cells. The current review focuses on possible mechanisms by which the expression of these proteins contribute to disease.
UR - http://www.scopus.com/inward/record.url?scp=33748513257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748513257&partnerID=8YFLogxK
U2 - 10.1016/j.ddmec.2006.05.009
DO - 10.1016/j.ddmec.2006.05.009
M3 - Review article
AN - SCOPUS:33748513257
SN - 1740-6765
VL - 3
SP - 177
EP - 184
JO - Drug Discovery Today: Disease Mechanisms
JF - Drug Discovery Today: Disease Mechanisms
IS - 2
ER -